Cluster 1 — The advertiser opportunity is three categories, not one
The GLP-1 advertiser set is not a vertical. It is three distinct buying centers, each with its own budget, its own motion, and its own timing.
Prescription and telehealth — the brands directly in the therapy: telehealth platforms, weight-management services, and the manufacturers themselves. This layer is spending now, and it is native to social. Lead generation, consultation booking, subscription conversion.
Adjacency brands — protein, supplements, fitness, food, apparel, beauty. This is the largest and most durable layer, and it is the one most category strategies miss entirely because it does not look like "GLP-1 spend" on a media plan. It is spend by every category adapting to a consumer whose appetite, routine, and body have changed.
Retail and distribution — the channels where the consumer now transacts: mass retail, pharmacy, and retail-media networks. Store traffic, basket expansion, and the cash-pay oral supply now sold directly through major retailers.
Signal. GLP-1 splits into three advertiser layers, each with its own buyer, budget, and motion.
Implication. A platform that maps all three is selling a category strategy, not a single drug-brand media buy — and it reaches the durable spend the single-buy framing never sees.
Action. Prioritize by layer: prescription spends now, adjacency is the durable wave, retail is the conversion tie-in. Sequence the pitch accordingly.
Cluster 2 — The access war is over; distribution and trust win
The gray market that built the telehealth GLP-1 boom has been closed — by federal action and a landmark settlement, in sequence, over the first half of 2026.
In February 2026, Novo Nordisk sued Hims & Hers for patent infringement over its compounded semaglutide products, days after Hims launched and then pulled a low-cost compounded pill under regulatory pressure. By March 9, 2026, the two had resolved the dispute: Novo dismissed its suit, and Hims agreed to sell Novo's FDA-approved Ozempic and Wegovy on its platform while ceasing the advertising and marketing of compounded GLP-1 drugs except where medically necessary. Novo reserved the right to refile — this is a resolution, not a permanent peace.
In parallel, the regulatory door closed. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances. The public comment period closed at the end of June 2026; a final determination is now pending. Combined with the resolution of the underlying shortages in 2024–2025, the proposal forecloses the last large-scale legal pathway for compounded supply. At its 2024 peak, compounded product had reached roughly 30% of total US GLP-1 supply.
Signal. Federal and state action plus a landmark settlement closed the compounded-GLP-1 gray market across 2026.
Implication. Competition shifts from price to trust and clinical legitimacy. The category that once competed on a cheaper copy now competes on credibility — a structural tailwind for education-led messaging.
Action. Move advertisers from price-led acquisition to education-first funnels with clinician-led retargeting. The brands that win this phase are the ones that look most legitimate, not the ones that look cheapest.
Cluster 3 — Oral pills widen the audience
The single largest adoption barrier in the category — the needle — is falling. Two oral GLP-1s are now approved and in market.
Novo Nordisk's oral Wegovy pill was approved in December 2025 and launched in January 2026; it has since driven more than 600,000 US prescriptions, an early signal that the oral format expands rather than merely converts the existing base. Eli Lilly's Foundayo (orforglipron) was approved on April 1, 2026 — the first GLP-1 pill that can be taken any time of day without food or water restrictions — with self-pay pricing starting at $149 per month for the lowest dose. Both pills' $149 floor stems from a manufacturer pricing agreement reached with the administration; eligible Medicare Part D patients can access these for $50 per month beginning July 1, 2026, pulling the audience further toward older adults.
A pill is not just a new SKU. It is a different consumer, reachable with a different story. Five creative hypotheses now open — to test, not to assume: needle-averse (the population that rejected injectables outright, now addressable for the first time); travel and convenience (no refrigeration, no weekly injection schedule); younger and lifestyle-led (a pill reads as less medical, broadening the creative register); price-sensitive (the $149 entry dose is the most accessible branded GLP-1 yet, and the Medicare floor extends it); and stigma-conscious (no visible "medical patient" identity attached to a daily pill).
Signal. Two approved oral GLP-1s remove the needle barrier; the addressable audience widens materially.
Implication. Oral pills create new creative hypotheses — not guaranteed segments — around convenience, stigma, price, and travel.
Action. Build two distinct audience hypotheses — injectable-converters versus pill-new-entrants — and test separate creative against each. Do not collapse them into one message.
Cluster 4 — The biggest spend isn't the drug
The most durable money in this category is not the therapy. It is every category adapting to the GLP-1 consumer — and the behavioral shift is now documented in peer-reviewed data, not anecdote.
A peer-reviewed study in the Journal of Marketing Research (Cornell, December 2025), drawn from a large consumer purchase panel, measured household spend within roughly six months of GLP-1 adoption: grocery spend down 5.3% overall and 8% among higher-income households, restaurant spend down 8%. Appetite changed; the basket changed with it.
That decline in one category is an opening in others. Protein and nutrition: GLP-1-driven muscle loss makes protein a clinical necessity, not a preference; major food brands have launched products built specifically for this consumer. Fitness and activewear: new routines and renewed confidence drive gym, equipment, and apparel spend. Food and dining: a smaller appetite raises the standard — every calorie has to earn its place, favoring high-protein, better-for-you positioning. Supplements and gut health: appetite suppression drives demand for micronutrient and digestive support.
Signal. Documented behavior change — grocery down 5.3% (8%+ for higher earners), restaurants down 8% — measured in a peer-reviewed panel.
Implication. Adjacency spend is the larger, more durable wave, concentrated in everyday consumer categories rather than in pharma.
Action. Pitch GLP-1 as a lifestyle shift that activates dozens of advertiser categories — not as a niche health vertical. The brief that frames it narrowly leaves the durable spend on the table.
Cluster 5 — Compliance is the new creative brief
In a tightening enforcement environment, what an advertiser is allowed to say has become as strategic as what it wants to say. Across 2025–2026, the FDA and FTC escalated action against misleading GLP-1 claims, including a batch of warning letters to telehealth firms and online clinics in early 2026. The cost of a non-compliant creative is no longer reputational alone — it is wasted production and media cycles.
What clears depends on who is advertising. Prescription and telehealth advertisers — regulated, and able to reference the therapy under their own obligations. Clears: eligibility explainers, clinician-led education, "talk to a licensed provider" framing. Needs review: efficacy claims, creator testimonials, transformation timelines. Avoid: guaranteed outcomes, off-label use, body-shaming hooks.
Adjacency and CPG advertisers — must never imply drug equivalence. Clears: "support your protein routine," meal-planning and strength content, retail availability and refill messaging. Needs review: "GLP-1 support" product claims, supplement efficacy claims, before/after stories. Avoid: "Ozempic alternative," "works like GLP-1," any compounded-equivalence framing.
This framework is StratSignal's editorial read of observed enforcement and standard platform ad policy. It is not legal advice; validate against current platform policy before activation.
Signal. Enforcement is tightening, and compliance now gates whether a creative ever runs.
Implication. The platform that can help advertisers pre-clear creative against the real enforcement line removes a cost the advertiser is otherwise absorbing blind.
Action. Treat compliance fluency as a capability, not a constraint — the platform that proves it owns the category's most anxious advertisers.
Cluster 6 — The category's spend follows trusted discovery
Every platform sells a different job. In a category rebuilt around trust, the job GLP-1 advertisers now need most is the one that carries a consumer from forming a health decision to acting on it — in a brand-safe, compliant environment, without a handoff.
That job is trusted discovery: the bridge from brand-building, where long-term category equity is formed, to performance, where a funded action happens. The category's structural shift — away from price, toward legitimacy; away from the needle, toward a wider audience; away from the drug, toward the adjacency economy — concentrates value at exactly that bridge. Search captures the consumer who has already decided. Pure-performance environments capture the click but not the decision. The consumer in this category is still forming the decision, and is doing it where they research, evaluate, and act on health.
The platform that wins this category is the one that can prove three things: that its environment is where this consumer actively evaluates health decisions; that it carries the consumer across the whole arc rather than at one end; and that it can do so inside the compliance line the category now demands. Reach is not the differentiator. Trusted discovery is.
Signal. The category's structural shifts all concentrate value at the bridge from brand-building to funded action.
Implication. Advertisers will reward the platform that owns trusted discovery — a credible health-decision environment with a compliant path to action — over the platform with the largest raw reach.
Action. The platform that can prove it owns trusted discovery, with first-party evidence of health-decision behavior and a compliant conversion path, wins the category's durable spend.